Analyzing the Decline in Moderna Stock Today

Moderna stock is trading -15.31% below its average target price of $138.52 after dropping -4.4% during today's afternoon session. Analysts are giving the Large-Cap Biotechnology company an average rating of buy and target prices ranging from $60.0 to $310.0 per share.

The stock has an average amount of shares sold short at 7.2%, and a short ratio of 6.93. The company's insiders own 9.6% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 73.0% of Moderna's shares being owned by this investor type.

Institutions Invested in Moderna

Date Reported Holder Percentage Shares Value
2024-03-31 Baillie Gifford and Company 12% 44,655,817 $5,238,573,783
2023-12-31 Vanguard Group Inc 9% 33,907,072 $3,977,638,533
2023-12-31 Blackrock Inc. 7% 25,301,692 $2,968,141,426
2023-12-31 State Street Corporation 4% 14,623,723 $1,715,508,909
2023-12-31 Flagship Pioneering Inc. 3% 9,666,038 $1,133,922,894
2023-12-31 Theleme Partners LLP 2% 7,349,456 $862,164,665
2023-12-31 Wellington Management Group, LLP 2% 7,225,579 $847,632,654
2023-12-31 Geode Capital Management, LLC 2% 6,549,461 $768,317,253
2023-12-31 FMR, LLC 2% 6,393,351 $750,003,990
2023-12-31 Goldman Sachs Group Inc 1% 4,551,626 $533,951,234

Besides an analyst consensus of some upside potential, other market factors point to there being positive market sentiment on Moderna.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.